FINAL_VeruIncLogo_RGB_300dpi.jpg
Veru to Present at the 2024 Cantor Global Healthcare Conference
September 11, 2024 08:30 ET | Veru Inc.
MIAMI, FL, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
FINAL_VeruIncLogo_RGB_300dpi.jpg
Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results
August 08, 2024 06:30 ET | Veru Inc.
--Phase 2b QUALITY study of enobosarm in combination with semaglutide (Wegovy®*) exceeds targeted full enrollment of >150 patients-- --Topline data for primary endpoint of lean body mass expected...
FINAL_VeruIncLogo_RGB_300dpi.jpg
Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024
August 01, 2024 08:30 ET | Veru Inc.
MIAMI, FL, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
FINAL_VeruIncLogo_RGB_300dpi.jpg
Veru to Participate in the BTIG Virtual Biotechnology Conference
July 29, 2024 08:30 ET | Veru Inc.
MIAMI, FL, July 29, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
FINAL_VeruIncLogo_RGB_300dpi.jpg
Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism
July 02, 2024 08:30 ET | Veru Inc.
MIAMI, FL, July 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
FINAL_VeruIncLogo_RGB_300dpi.jpg
Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions
June 24, 2024 08:30 ET | Veru Inc.
MIAMI, FL, June 24, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
FINAL_VeruIncLogo_RGB_300dpi.jpg
Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024
June 18, 2024 16:05 ET | Veru Inc.
MIAMI, FL, June 18, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
FINAL_VeruIncLogo_RGB_300dpi.jpg
Veru Reminds Shareholders to Vote in Advance of Tomorrow’s Deadline for 2024 Annual Meeting of Shareholders
June 17, 2024 16:45 ET | Veru Inc.
MIAMI, FL, June 17, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
FINAL_VeruIncLogo_RGB_300dpi.jpg
Veru to Present at the American Diabetes Association's 84th Scientific Sessions
June 10, 2024 08:30 ET | Veru Inc.
MIAMI, FL, June 10, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
FINAL_VeruIncLogo_RGB_300dpi.jpg
Veru to Present at the Jefferies Global Healthcare Conference
May 22, 2024 08:30 ET | Veru Inc.
MIAMI, FL, May 22, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...